CRISPR Therapeutics Slides 9% After $500M Debt Surprise — The Cost of Curing Disease?
This episode analyzes CRISPR Therapeutics' recent 9% stock decline following a $500 million convertible notes offering. The discussion covers the company's financial results, commercial progress with Casgevy, and market implications.